

ESMO ADVANCED COURSE

BARCELONA SPAIN 25-26 NOVEMBER 2024

Co-Chairs

Thierry Conroy, France Sylvie Lorenzen, Germany



ESMO ADVANCED COURSE PROGRAMME PANCREATIC CANCER: FROM STANDARD TREATMENT TO INDIVIDUALIZATION

Barcelona, Spain 25-26 November 2024

CO-CHAIRS

Thierry Conroy, France Sylvie Lorenzen, Germany **SPEAKERS**

Michel Ducreux, France
Anna Falanga, Italy
Angela Lamarca, Spain
Teresa Macarulla, Spain
Emmanuel Mitry, France
Cindy Neuzillet, France
Gerald Prager, Austria
Oliver Strobel, Austria
Jean-Luc Van Laethem, Belgium
Valérie Vilgrain, France

LEARNING OBJECTIVES

- To get an updated overview of current treatment standards in pancreatic cancer discussed interactively based on patient cases, study data and guideline recommendations
- To work through the most important issues in an interdisciplinary way, and to ask the question: What do I do in my daily practice
 on next Monday?
- To think outside the box what could be current and future individualized therapy strategies?
- To inform individual clinical decision-making through the recommendations from ESMO Clinical Practice Guidelines

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4, 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



Monday, 25 November 2024

09:00-09:10	Welcome and introduction
10'	Welcome and learning objectives introduction Thierry Conroy, FR and Sylvie Lorenzen, DE
09:10-10:35	Session 1 – Resectable pancreatic cancer Chairs: Sylvie Lorenzen, DE and Gerald Prager, AT
20'	Imaging, work-up, staging, and how to assess resectability Valérie Vilgrain, FR
25'	Resection and pathology; prognostic factors Oliver Strobel, AT
20'	Lessons from adjuvant therapies Thierry Conroy, FR
20'	Q&A
10:35-11:05	Coffee break
11:05-12:15	Session 2 – Neoadjuvant and induction approaches Chairs: Emmanuel Mitry, FR and Oliver Strobel, AT
20'	Pancreatic cancer in the era of neoadjuvant treatment: Oncological perspective Sylvie Lorenzen, DE
15'	'Induction therapy' for borderline resectable pancreatic cancer Gerald Prager, AT
15'	Specific surgical questions after neoadjuvant or induction therapies Oliver Strobel, AT
20'	Q&A
12:15-13:15	Lunch
13:15-14:35	Session 3 – Metastatic pancreatic cancer Chairs: Michel Ducreux, FR and Jean-Luc Van Laethem, BE
20'	What are the best options as first line therapy? Michel Ducreux, FR
20'	What are the best options as second line therapy? Teresa Macarulla, ES
20'	What is the best sequence? Results of transcriptomic signatures Emmanuel Mitry, FR
20'	Q&A

14:35-15:05	Coffee break
15:05-16:45	Session 4 – Specific situations Chairs: Thierry Conroy, FR and Sylvie Lorenzen, DE
20'	Does personalized treatment approach by molecular profiling lead to better prognosis of metastatic pancreatic cancer? Angela Lamarca, ES
20'	Current treatment strategies for advanced pancreatic cancer in the elderly Jean-Luc Van Laethem, BE
20'	Venous thromboembolism in pancreatic cancer patients: ESMO Clinical Practice Guideline Anna Falanga, IT
20'	Interventions for improving palliative care and quality of life in pancreatic cancer Cindy Neuzillet, FR
20'	Q&A
19:00	Networking dinner

Tuesday, 26 November 2024

09:00-12:30	Workshop sessions Three workshop sessions where clinical cases are presented by speakers with interactive questions and discussion with the audience (delegates will attend all 3 sessions on a rotation basis) 60' Workshop time
Workshop 1 60'	Current insights of chemotherapy for metastatic pancreatic cancer Michel Ducreux, FR and Gerald Prager, AT
Workshop 2 60'	How I treat locally advanced pancreatic cancer in 2024? Optimal treatment strategy? Teresa Macarulla, ES
11:00-11:30	Coffee break
Workshop 3 60'	What is the next cutting-edge treatment for pancreatic cancer? Time for precision medicine? Angela Lamarca, ES
12:30-12:45	Feedback on the workshops Chairs: Angela Lamarca, ES, Teresa Macarulla, ES and Gerald Prager, AT
12:45-12:50	Conclusion and farewell Thierry Conroy, FR and Michel Ducreux, FR
12:50-13:50	Lunch